Liquidia (LQDA) Other Non-Current Assets (2019 - 2026)
Liquidia (LQDA) posted Other Non-Current Assets of $19.3 million for Q2 2026, up 14.24% on a QoQ basis from $16.9 million in Q1 2026, and down 13.89% year-over-year from $22.4 million in Q2 2025.
Analysis
Liquidia (LQDA) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Liquidia has reported Other Non-Current Assets for 8 years, with the latest figure at $19.3 million in Q2 2026.
- On a quarterly basis, Other Non-Current Assets fell 13.89% year-over-year to $19.3 million in Q2 2026; TTM through Jun 2026 was $19.3 million, a 13.89% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, up 20.64% from the prior year.
- Other Non-Current Assets was $19.3 million for Q2 2026 at Liquidia, up from $16.9 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $22.4 million in Q2 2025, with the low at $224000.0 in Q1 2024.
- Average Other Non-Current Assets over 5 years is $6.5 million, with a median of $307000.0 recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets slipped 27.04% in 2024, then surged 9908.93% in 2025.
- Over 5 years, Other Non-Current Assets stood at $307000.0 in 2022, then fell by 6.51% to $287000.0 in 2023, then soared by 3704.18% to $10.9 million in 2024, then gained by 20.64% to $13.2 million in 2025, then soared by 46.57% to $19.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $19.3 million (Q2 2026), $16.9 million (Q1 2026), and $13.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 442.18 Bn | 435.61 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 366.59 Bn | 359.45 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 266.49 Bn | 258.80 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 9.94 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | 5.50 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 42.45 Mn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 86.76 Mn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 239.50 Mn |
| 10 | Liquidia | 6.12 Bn | 5.83 Bn | 160.92 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.31 Mn |
| Mar 31, 2026 | 16.90 Mn |
| Dec 31, 2025 | 13.17 Mn |
| Sep 30, 2025 | 8.95 Mn |
| Jun 30, 2025 | 22.42 Mn |
| Mar 31, 2025 | 15.54 Mn |
| Dec 31, 2024 | 10.92 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 224,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 287,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 260,000.00 |
| Mar 31, 2023 | 307,000.00 |
| Dec 31, 2022 | 307,000.00 |
| Sep 30, 2022 | 307,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Mar 31, 2022 | 307,000.00 |
| Dec 31, 2021 | 311,000.00 |
| Sep 30, 2021 | 312,925.00 |